Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

  title={Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study},
  author={Messoud Ashina and Stewart J. Tepper and Jan Lewis Brandes and Uwe Reuter and Guy P. Boudreau and David Dole{\vz}il and Sunfa Cheng and Feng Zhang and Robert A. Lenz and Jan Klatt and Daniel D. Mikol},
  pages={1611 - 1621}
Background Erenumab was effective and well tolerated in a pivotal clinical trial of chronic migraine. Here, we evaluated efficacy and safety of monthly erenumab (70 mg or 140 mg) versus placebo in the subgroup of patients who had previously failed preventive treatment(s) (≥ 1, ≥ 2 prior failed medication categories) and in patients who had never failed. Methods Subgroup analyses evaluated change from baseline in monthly migraine days; achievement of ≥ 50% and ≥ 75% reduction in monthly migraine… 

Figures and Tables from this paper

Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial
Erenumab was associated with clinically relevant improvements in all efficacy endpoints and was well tolerated across all subgroups of Japanese migraine patients with/ without prior preventive treatment failure and with/without concomitant preventive treatment.
Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure
Galcanezumab is consistently efficacious versus placebo in reducing monthly migraine headache days and several other key outcomes in patients with chronic migraine who have failed ≥2 or ≥1 preventives previously.
Two-year efficacy and safety of erenumab in participants with episodic migraine and 2–4 prior preventive treatment failures: results from the LIBERTY study
Efficacy was sustained over 112 weeks in individuals with difficult-to-treat EM for whom 2–4 prior migraine preventives had failed and erenumab treatment was safe and well tolerated, in-line with previous studies.
Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study
Fremanezumab demonstrated sustained efficacy up to 6 months and was well tolerated in patients with episodic migraine or chronic migraine and documented inadequate response to multiple migraine preventive medication classes.
A prospective real-world analysis of erenumab in refractory chronic migraine
Erenumab may be an effective and well tolerated therapy for medically refractory CM patients with and without medication overuse and at least one side effect was reported by 48% of patients at month 1, 22% at month 3 and 15% at months 6.
The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal
The available data suggest that erenumab 140 mg monthly might be preferred over the 70‷mg monthly dose in patients with EM or CM and prior preventive treatment failures, and further data are needed to assess the long-term efficacy in clinical practice of the two doses.
The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response
For erenumab-treated patients achieving ≥50% response, the actual reduction in MMD was almost twice that of the overall population, providing context for setting realistic expectations regarding actual treatment benefit experienced by patients responding to treatment.
Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response
Significant improvements in efficacy were observed with fremanezumab compared with placebo, even in patients who had previously experienced inadequate response to 4 different classes of migraine preventive medications.
Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
Erenumabis is a treatment option for CM patients who failed all first-line preventives in addition to BoNTA and showed efficacy in a real-world setting similar to data from clinical trials.


Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
Significant reductions from baseline were observed for onabotulinumtoxinA for headache and migraine days, cumulative hours of headache on headache days and frequency of moderate/severe headache days, which in turn reduced the burden of illness in adults with disabling chronic migraine.
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
The results of PREEMPT 2 demonstrate that onabotulinumtoxinA is effective for prophylaxis of headache in adults with chronic migraine, with few treatment-related adverse events.
Adherence to oral migraine-preventive medications among patients with chronic migraine
Adherence to OMPMs is low among the US CM population at six months and worsens by 12 months, and except for amitriptylines, nortriptyline, gabapentin, and divalproex, which had significantly lower odds of adherence when compared to topiramate.
The Importance of Placebo in Headache Research
Factors which influence the placebo response in clinical trials, such as expectation, blinding, route of application of drugs and age, gender and geographical distribution are reviewed.
Preventive treatment in migraine and the new US guidelines
The updated US guidelines for the prevention of migraines are described and the major studies from which these guidelines were derived are outlined.
Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial
Objective.—To evaluate the efficacy and safety of topiramate (100 mg/day) compared with placebo for the treatment of chronic migraine.
Clinically Significant Drug Interactions with Agents Specific For Migraine Attacks
Nearly all the clinically important interactions between the ergopeptide antimigraine agents and currently marketed drugs are likely to have already come to notice.
Defining the Differences Between Episodic Migraine and Chronic Migraine
Recognizing that both disorders are on the spectrum of migraine, this review serves as a guide to define the disease state of CM as distinct from EM in terms of clinical, epidemiological, sociodemographic, and comorbidity profiles.
Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor
Results indicate AMG 334 is a potent, selective, full antagonist of the CGRP receptor and show in vivo dose-dependent target coverage in cynos, currently in clinical development for the prevention of migraine.